Benchmarking 2027: Shifting Priorities in U.S. Health Infrastructure

By: Women's HealthX Editorial
08/17/2026

As healthcare organizations navigate tightening compliance mandates, evolving reimbursement frameworks, and shifting health economics, the single most critical asset for leadership is operational visibility into what their industry counterparts are executing right now.

Ahead of the Women's HealthX marketplace in Boston this December, a cross-functional steering committee of health plans, hospital networks, biopharma innovators, and enterprise employers has launched the definitive 2026 U.S. Health Infrastructure Survey.

The objective of this brief, multi-state index is to bypass abstract market fluff and map out exactly how the country's elite healthcare stakeholders are practically structuring their 2027 budgets, clinical protocols, and technology procurement guidelines.

Some of the questions we are asking:

  • Health Plans & Payers "What is the biggest operational barrier to expanding women's health coverage?"
  • Health Systems & Providers "What is the biggest women's health priority for health systems over the next 24 months?"
  • Pharma & Life Sciences "What is the biggest commercial hurdle facing women's health innovation?"
  • Employers & Benefits Leaders "Which women's health challenge creates the greatest workforce impact?"

By contributing just 60 seconds of your operational insight to the index, you will ensure your specific sector's parameters are accurately represented. In return for your participation, you will secure a priority, pre-ordered copy of the completed 30-page intelligence report when the final data drops this September! See where your direct peer groups are drawing their line in the sand for the upcoming fiscal year.

Women’s HealthX 2026 | From Rhetoric to Results

Encore Boston Harbor | December 3-4 2026

Bypass abstract market rhetoric to evaluate real-world health economics, regulatory compliance mandates, and care delivery systems. Join the region's foremost health plan medical directors, hospital COOs, biopharma innovators, and enterprise benefits buyers anchoring our 2026 tracks.